BioWorld
  • BioWorld Home
  • About Us
  • Contact BioWorld

BioWorld Perspectives

news, analysis, debates, commentary and camaraderie related to the development of biotechnology drugs
  • Blog Home
  • Editorial Staff
  • About BioWorld
  • Contact Us
  • Log In

Lessons learned from You-Know-Who

September 2, 2015 – 3:47 pm | By Mari Serebrov | No comments yet

Duchesnay Inc.’s 15-minutes of fame for its morning sickness drug arguably turned into a few hours’ worth by time the drugmaker complied with an FDA warning letter demanding a corrective ad to offset the omission of risk information in paid…

Share

Read more
Posted in FDA, social media |

The next episode of the American horror story

July 24, 2015 – 7:18 pm | By Mari Serebrov | No comments yet

You’ve likely heard the terrified screams induced by the cost of pricey cancer drugs, Gilead Sciences Inc.’s twin hepatitis C therapies and Vertex’s cystic fibrosis breakthroughs. And you may have been rattled by the nightmarish predictions about how a new…

Share

Read more
Posted in aging, Alzheimer's, Biotechnology Industry Organization, Drug pricing |

Utopia, dystopia: Separating truth from fiction in bioethics discussions

June 2, 2015 – 11:05 pm | By Jennifer Boggs | No comments yet

Let’s face it: Imagining the means of humanity’s ultimate destruction makes for great entertainment. There are no shortages of novels, movies and television shows featuring threats of global annihilation – zombie viruses, meteors hurtling through space, nuclear warfare – or…

Share

Read more
Posted in bioethics, Biotechnology, ethics, human germline engineering |

A world of intrigue, from Missoula to Mars: BioWorld’s 9th Annual Summer Reading List

May 26, 2015 – 5:31 pm | By Marie Powers | No comments yet

Summer is not officially here, according to the calendar, but the first long weekend of the season brings thoughts of beaches, mountains, travel, relaxation, lazy days and active ones. No matter what floats your boat over summer vacation, a good…

Share

Read more
Posted in Summer reading |

You’ve come a long way, baby, but still a long way to go

May 4, 2015 – 1:43 pm | By Mari Serebrov | No comments yet

Patients have come a long way to get a say in the drug development and approval process. But there’s still some ground to cover if they’re going to move from the passive subject role to a 50-50 partnership that reminds…

Share

Read more
Posted in adcom, Drug pricing, FDA, Patient, Reimbursement |

As researchers unlock the brain’s mysteries, let’s not overlook the real questions

April 27, 2015 – 3:35 pm | By Marie Powers | No comments yet

Covering the American Academy of Neurology’s (AAN) 67th annual meeting in Washington – a gathering of nearly 13,000 clinicians, researchers, students, industry reps and even a few patients – was an exercise in exhaustion and a labor of love. I…

Share

Read more
Posted in biopharmaceutical, Biotech conferences, epilepsy, neurology |

Talk to your doctor: How even annoying DTC ads can contribute to patient communication

April 15, 2015 – 3:48 pm | By Jennifer Boggs | No comments yet

A few years ago I went to the nearby immediate care with a minor but irritating cough that wouldn’t go away. Three visits later – after two utterly ineffectual rounds of antibiotics and a prescription for a cough medicine that…

Share

Read more
Posted in Big pharma, direct to consumer |

Sharing deeply of ourselves: Still messy

March 27, 2015 – 10:16 pm | By Michael Fitzhugh | No comments yet

In the capital of digital sharing and over-sharing, Silicon Valley, contributing one’s whole genome to science in the name of fun and self-knowledge has never felt that controversial. Engineers share software code liberally every day on sites like GitHub and…

Share

Read more
Posted in genetics, Genomics, Patient, Precision medicine |

Patient engagement as important as the data

February 13, 2015 – 11:03 pm | By Mari Serebrov | No comments yet

The thought of having unfettered access to all the medical and genomic data of a million Americans had researchers gathered at the National Institutes of Health’s first workshop on precision medicine licking their lips. Almost giddy with excitement, they contemplated…

Share

Read more
Posted in Patient, Personalized medicine, Precision medicine |

Listening to the voice that matters

February 4, 2015 – 2:35 pm | By Mari Serebrov | No comments yet

Since being diagnosed with cancer a few months ago, I have been in an unwanted crash course on the patient perspective of everything I’ve been writing about biopharma for the past several years. It’s an eye-opener. Genetic testing, lack of…

Share

Read more
Posted in Cancer, Clinical Trial, Patient |
« Previous 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22 Next »

About this Blog

BioWorld Perspectives is the official blog for news, analysis, debates, commentary and camaraderie related to the development of biotechnology drugs.

Join the Conversation

Sign up for our blog!

Advertise Here!

Categories

  • Accelerated approval (3)
  • acquisition (1)
  • acute kidney injury (1)
  • adcom (4)
  • Addyi (1)
  • aging (3)
  • AIDS (1)
  • Alzheimer's (1)
  • antibiotics (4)
  • Antibody (2)
  • Asia (1)
  • Autism (1)
  • Big pharma (31)
  • bioethics (8)
  • Biologic (11)
  • biopharmaceutical (12)
  • Biosimilar (15)
  • Biotech conferences (13)
  • Biotechnology (103)
  • Biotechnology Industry Organization (14)
  • BLA (5)
  • Books (5)
  • Cancer (20)
  • Cardiovascular (3)
  • China (6)
  • chronic fatigue syndrome (3)
  • Clinic (6)
  • clinical study report (3)
  • Clinical Trial (23)
  • Clinical Trial Design (4)
  • Collaboration (6)
  • compassionate use (1)
  • Complete Response Letter (4)
  • Congress (5)
  • corporate tax (2)
  • Deals (7)
  • Diabetes (1)
  • direct to consumer (1)
  • DNA (4)
  • Drug Approval (19)
  • drug importation (2)
  • Drug pricing (17)
  • Ebola (1)
  • embryonic stem cell research (2)
  • emerging markets (3)
  • epilepsy (2)
  • ethics (5)
  • European Medicines Agency (6)
  • evolution (1)
  • executive salaries (1)
  • FDA (39)
  • Financing (26)
  • Flu (1)
  • FOB (2)
  • Follow-on biologic (3)
  • FTC (1)
  • Gene Therapy (5)
  • generic (3)
  • genetics (7)
  • Genomics (10)
  • gift guide (1)
  • Healthcare reform (7)
  • HIV (1)
  • human germline engineering (2)
  • immunotherapy (4)
  • IND (3)
  • Initial public offering (1)
  • innovation (1)
  • Investigational New Drug Application (4)
  • IPO (6)
  • License (3)
  • M&A (8)
  • market capitalization (1)
  • Methicillin-resistant Staphylococcus aureus (1)
  • mitochondria (1)
  • multidrug resistance (2)
  • mutation (1)
  • National Institutes of Health (2)
  • NDA (4)
  • neurology (4)
  • neuroprostheses (1)
  • neuroprosthetic (1)
  • New Drug Application (9)
  • Obesity (1)
  • OIG (1)
  • Orphan disease (8)
  • pandemic (1)
  • partnering (2)
  • patent cliff (2)
  • Patents (6)
  • Patient (7)
  • patient assistance program (2)
  • PDUFA (5)
  • Personalized medicine (7)
  • Pharmaceutical (22)
  • Phase I (6)
  • Phase II (5)
  • Phase III (7)
  • Pipeline (6)
  • Precision medicine (4)
  • Preclinical (2)
  • prostate cancer (1)
  • R&D (1)
  • Rare disease (3)
  • Reimbursement (12)
  • REMS (1)
  • RNAi (2)
  • SEC (2)
  • sequestration (2)
  • Series A (1)
  • Shareholder value (1)
  • siRNA (2)
  • social media (2)
  • Stem cell (2)
  • Summer reading (5)
  • Supplemental new drug application (2)
  • TB (1)
  • traumatic brain injury (1)
  • Tuberculosis (2)
  • Type 2 Diabetes (1)
  • Uncategorized (22)
  • Vaccine (5)
  • venture captial (9)
  • Video (5)
  • virus (3)

Recent Posts

  • If no one reads it, what’s the purpose of a drug label?
  • The opioid crisis: A venture in need of a GAIN?
  • Real-world optics of biopharma price hikes
  • Science for the season: BioWorld’s 11th annual Holiday Gift Guide
  • Drug quality from a patient’s perspective

Tags

ABH Amgen Inc ASCO BIO Biotechnology Industry Organization bioworld BRIC Celgene Corp CEO China Clovis Oncology Inc Cynthia Robbins Roth Day Four Day Three Day Two Dendreon Corp DNA EST EU FDA HCV HIV IPO Janssen Labs Mama Namibia Mari Serebrov MBA Morgan Healthcare Conference New York New York Times NIH Nobel Prize PDUFA Pfizer Inc PR RNA Roche ROI San Diego San Francisco Seattle Genetics Inc SEC UK VC Vivus Inc

Calendar

April 2018
M T W T F S S
« Mar    
 1
2345678
9101112131415
16171819202122
23242526272829
30  
clarivate.com | BioWorld.com | bioworldmedtech.com
© Copyright 2018 | BioWorld Perspectives